info:eu-repo/semantics/article
A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine
Fecha
2020-07Registro en:
Bidart, Juan Esteban; Kornuta, Claudia Alejandra; Gammella, Mariela Vanesa; Gnazzo, Victoria; Soria, Ivana; et al.; A New Cage-Like Particle Adjuvant Enhances Protection of Foot-and-Mouth Disease Vaccine; Frontiers Media; Frontiers in Veterinary Science; 7; 7-2020; 1-12
2297-1769
CONICET Digital
CONICET
Autor
Bidart, Juan Esteban
Kornuta, Claudia Alejandra
Gammella, Mariela Vanesa
Gnazzo, Victoria
Soria, Ivana
Langellotti, Cecilia Ana
Mongini, Claudia
Galarza, Roxana
Calvinho, Luis Fernando
Lupi, Giuliana Antonella
Quattrocchi, Valeria
Marcipar, Iván Sergio
Zamorano, Patricia Ines
Resumen
Foot-and-Mouth Disease (FMD) is an acute viral disease that causes important economy losses. Vaccines with new low-cost adjuvants that stimulate protective immune responses are needed and can be assayed in a mouse model to predict their effectiveness in cattle. Immunostimulant Particle Adjuvant (ISPA), also known as cage-like particle adjuvant, consisting of lipid boxes of dipalmitoyl-phosphatidylcholine, cholesterol, sterylamine, alpha-tocopherol, and QuilA saponin, was shown to enhance protection of a recombinant vaccine against Trypanosoma cruzi in a mouse model. Thus, in the present work, we studied the effects on the magnitude and type of immunity elicited in mice and cattle in response to a vaccine based on inactivated FMD virus (iFMDV) formulated with ISPA. It was demonstrated that iFMDV–ISPA induced protection in mice against challenge and elicited a specific antibody response in sera, characterized by a balanced Th1/Th2 profile. In cattle, the antibody titers reached corresponded to an expected percentage of protection (EPP) higher than 80%. EPP calculates the probability that livestock would be protected against a 10,000 bovine infectious doses challenge after vaccination. Moreover, in comparison with the non-adjuvanted iFMDV vaccine, iFMDV–ISPA elicited an increased specific T-cell response against the virus, including higher interferon gamma (IFNγ)+/CD8+ lymphocyte production in cattle. In this work, we report for first time that an inactivated FMDV serotype A vaccine adjuvanted with ISPA is capable of inducing protection against challenge in a murine model and of improving the specific immune responses against the virus in cattle.